

DRUG QUANTITY MANAGEMENT POLICY – PER RX

POLICY: Corticosteroids (Nasal) – Mometasone Drug Quantity Management Policy – Per Rx

- mometasone furoate nasal spray (generic only)

REVIEW DATE: 04/13/2022

OVERVIEW

Mometasone furoate nasal spray (generic to prescription Nasonex[®], no longer available), a nasal corticosteroid, is indicated for:¹

- **Allergic rhinitis:**
 - For the **treatment of nasal symptoms** of seasonal and perennial allergic rhinitis in patients \geq 2 years of age.
 - For the **treatment of nasal congestion** associated with seasonal allergic rhinitis in patients \geq 2 years of age.
 - For the **prophylaxis of the nasal symptoms** of seasonal allergic rhinitis in patients \geq 12 years of age.
- **Nasal polyps**, treatment in patients \geq 18 years of age.

Dosing

Allergic Rhinitis

- Patients \geq 12 years of age: 2 sprays per nostril once daily (QD)
- Patients 2 to 11 years: 1 spray per nostril QD

Nasal Polyps

- Patients \geq 18 years of age: 2 sprays per nostril twice daily (BID). Dosing QD, may also be effective in some patients.

Availability

Mometasone nasal spray is available as a 17 g manual pump spray.¹ Each actuation delivers 50 mcg of mometasone furoate and there are 120 sprays per bottle.

In March 2022, the FDA-approval of Nasonex (mometasone furoate nasal spray) was changed from prescription to over-the-counter (OTC) status. Therefore, prescription brand Nasonex has been discontinued. Prescription generic products remain available. The OTC Nasonex 24HR Allergy product is NOT targeted in this policy.

POLICY STATEMENT

This Drug Quantity Management program has been developed to promote the safe, effective, and economic use of mometasone furoate nasal spray. If the Drug Quantity Management rule is not met for the requested medication at the point of service, coverage will be determined by the Criteria below. All approvals are provided for 3 years in duration.

Automation: None.

Drug Quantity Limits

Product	Strength and Form	Maximum Quantity per Rx
mometasone furoate nasal spray (generic only)	50 mcg/spray (120 sprays per 17 g bottle)	120 sprays/17 grams (1 bottle)*

* Quantity sufficient for a 30-day supply for all indications except the treatment of nasal polyps.

CRITERIA

1. If the patient is treating nasal polyps, approve up to 34 grams/240 sprays (2 bottles) per dispensing.
2. No other exceptions are recommended.

REFERENCES

1. Nasonex® [prescribing information]. Whitehouse Station, NJ: Merck; September 2020.